Women's Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Breast Cancer
Fulvestrant compared to anastrozole for treatment of advanced breast cancer
September 22nd, 2005
Fulvestrant was recently compared to anastrozole for the treatment of advanced breast cancer. "Fulvestrant, a new type of oestrogen receptor antagonist with no agonist effects, is now licensed in the EU and USA for the treatment of postmenopausal women with hormone-sensitive advanced breast cancer following progression on prior antioestrogen therapy. Approval was based on data from two phase III trials that demonstrated fulvestrant was at least as effective as the third-generation aromatase inhibitor (AI) anastrozole as a second-line treatment for advanced breast cancer," investigators in United Kingdom report. "The third-generation AIs letrozole and...
Source: Women's Health Weekly (2005-09-22)
|
